|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | |
| C07K 14/00 |
| (11) | Patento numeris | 2992013 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13721243.7 |
| Europos patento paraiškos padavimo data | 2013-04-29 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-03-09 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-12-04 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2013/038659 |
| Data | 2013-04-29 |
| (87) | Numeris | WO 2014/178820 |
| Data | 2014-11-06 |
| (72) |
CLARKE, Adam, AU
POLLARD, Matthew, AU
DOYLE, Anthony, Gerard, AT
BEHRENS, Collette, AU
YAMAGISHI, Tetsuo, AU
WILSON, David, S. Jr., US
POGUE, Sarah, L., US
TAURA, Tetsuya, US
|
| (73) |
Teva Pharmaceuticals Australia Pty Ltd,
Level 2 37 Epping Road, Macquarie Park, NSW 2113,
AU
|
| (54) | ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B |
| ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B |